CopenhagenNovo Nordisk stopped two heart trials for futility.
The result undercuts a theory that cooling inflammation, not cholesterol alone, prevents heart attacks.
A monitoring committee found HERMES and ATHENA, its ziltivekimab trials, unlikely to succeed after ZEUS also failed.
Novo has not said whether it will pursue the inflammation approach in other diseases.
Sources: STAT